Obsidian Therapeutics (NASDAQ:OBX) Cut to “Sell” at Wall Street Zen

Obsidian Therapeutics (NASDAQ:OBX) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday, Wall Street Zen reports.

A number of other equities research analysts have also recently commented on OBX. Zacks Research upgraded Obsidian Therapeutics to a “hold” rating in a research note on Thursday, August 6th. Lifesci Capital initiated coverage on shares of Obsidian Therapeutics in a research report on Tuesday, August 18th. They set an “outperform” rating and a $43.00 price target for the company. Weiss Ratings initiated coverage on shares of Obsidian Therapeutics in a research report on Wednesday, September 2nd. They set a “sell (d-)” rating for the company. TD Cowen assumed coverage on shares of Obsidian Therapeutics in a report on Thursday, August 6th. They set a “buy” rating for the company. Finally, Leerink Partners began coverage on shares of Obsidian Therapeutics in a research report on Tuesday, September 22nd. They issued an “outperform” rating and a $32.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Obsidian Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $39.00.

Obsidian Therapeutics Stock Performance

Shares of Obsidian Therapeutics stock opened at $12.56 on Friday. The stock’s fifty day simple moving average is $14.28. Obsidian Therapeutics has a 12 month low of $9.60 and a 12 month high of $49.97.

Obsidian Therapeutics (NASDAQ:OBX) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($1.23) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.80). Research analysts anticipate that Obsidian Therapeutics will post -1.81 EPS for the current year.

About Obsidian Therapeutics

Obsidian Therapeutics is a biotechnology company developing engineered cell therapies for cancer. Its research focuses on modifying immune cells to improve their ability to target tumors and function within the body. The company’s programs include OBX-115, an engineered tumor-infiltrating lymphocyte (TIL) therapy being developed for solid tumors. Obsidian’s cytoDRiVE platform is designed to regulate the activity of therapeutic proteins using small molecules, with the aim of controlling and optimizing cell therapies.